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Abstract
Summary In a retrospective cohort study using the General
Practice Research Database (GPRD), there was a greater
association of venous thromboembolism (VTE) in osteo-
porotic than in non-osteoporotic female patients. No greater
association was shown in treated patients with strontium
ranelate or alendronate compared to untreated osteoporotic
female patients.
Introduction We explored the risk of VTE in usual practice
in osteoporotic and non-osteoporotic women with and
without anti-osteoporotic treatment.
Methods A retrospective study was conducted using the
GPRD in the UK. The cohorts consisted of untreated
osteoporotic women (N=11,546), osteoporotic women
treated with alendronate (N=20,084), or strontium ranelate
(N=2,408), and a sample of non-osteoporotic women (N=
115,009). Cohorts were compared using a Cox proportional
hazards regression model.
Results There was a significantly increased relative risk for
VTE in untreated osteoporotic women versus non-
osteoporotic women (annual incidence 5.6 and 3.2 per
1,000 patient–years, respectively; relative risk 1.75 [95%
confidence interval (CI), 1.09–1.84]). Results were con-
firmed using adjusted models. The annual incidences of
VTE in osteoporotic patients treated with strontium ranelate
and alendronate were 7.0 and 7.2 per 1,000 patient–years,
respectively, with no significant difference between un-
treated and treated patients whatever the treatment. Adjust-
ed hazard ratios for treated versus untreated osteoporotic
women were 1.09 (95% CI, 0.60–2.01) for strontium
ranelate and 0.92 (95% CI, 0.63–1.33) for alendronate.
Conclusion This study shows a greater association of VTE
in osteoporotic compared to non-osteoporotic patients, but
does not show any greater association in treated patients with
strontium ranelate or alendronate compared to untreated
osteoporotic patients.
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Introduction
The incidence of venous thromboembolism (VTE) varies
according to the presence of a number of risk factors;
most notable are age, immobilisation, hospitalisation,
and surgery [1, 2]. In addition, ageing is accompanied by
an increasing incidence of chronic diseases, which can
impair general health status, and may also indirectly
increase the risk for VTE [3]. One such chronic disease
is osteoporosis, which leads to an increased risk for
fracture, especially when it is associated with other risk
factors, such as age, sex, history of fractures, low body
mass index (BMI), or a recent fall [4–6]. The occurrence
of osteoporotic fracture may in turn lead to immobilisa-
tion, hospitalisation, and surgery. By accumulating risk
factors, ageing osteoporotic patients may, therefore, be
particularly susceptible to VTE, though this has never
been demonstrated.
The most commonly used agents to treat osteoporosis
are bisphosphonates, calcitonin, raloxifene, parathyroid
hormone, and strontium ranelate [7–10]. Analyses of the
pooled populations of phase III studies for strontium
ranelate have shown a slight increase in the annual
incidence of VTE, with a relative risk of 1.4 (95%
confidence interval [CI], 1.0–2.0) versus placebo [11].
However, this increased risk with strontium ranelate
remains weak when compared with treatments with a clear
biological rationale for increasing VTE, such as selective
oestrogen–receptor modulators or oestrogen replacement
treatment [12–15].
The objectives of this study were to explore the
incidence of VTE and its risk factors in osteoporotic and
non-osteoporotic women and to investigate the relationship
between the incidence of VTE and the anti-osteoporotic
treatments strontium ranelate and alendronate sodium.
Alendronate sodium is the most highly prescribed
bisphosphonate in the UK and has never been associated
with an increased risk for VTE.
Methods
Data source
The General Practice Research Database (GPRD) contains
anonymous electronic medical records from primary care in
the UK. It encompasses a representative sample of
approximately 6% of the population from around 450
practices throughout the UK. The GPRD is currently
operated and maintained by a division of the UK Medicines
and Healthcare Products Regulatory Agency (MHRA). The
database includes information on patient demographics,
outpatient drug prescriptions, symptoms and medical
diagnoses, referrals to specialists and hospitals, outpatient
laboratory test results, and lifestyle factors (e.g., BMI,
blood pressure, smoking, and alcohol consumption). Con-
tributing general practitioners are required to meet specific
recording standards to be considered “up-to-standard”
(UTS). The accuracy and completeness of data held in the
GPRD has been confirmed [16, 17], as well as its validity
for the study of VTE [18]. As a result, the GPRD data is
considered to be of sufficiently high quality for medical
research. This project was approved by the Independent
Scientific Advisory Committee for MHRA database
research on 18 February 2008.
Study design and population
A retrospective cohort study was conducted on permanently
registered female patients aged 50 years or older who had a
general practice consultation for osteoporosis or who
received at least one prescription for strontium ranelate or
alendronate sodium, following the date of launch of
strontium ranelate in the UK (December 2, 2004).
Only patients with 6 months of UTS follow-up before
the index date were included. The study population
included patients with a first ever record and patients with
a history of primary osteoporosis and/or drug prescription.
The following cohorts were analysed: one cohort per anti-
osteoporotic treatment consisting of new prescriptions only
as proposed by Ray et al. [19]; one cohort of untreated
osteoporotic patients according to anti-osteoporotic drug
prescriptions; and a reference cohort of non-osteoporotic
female patients, which consisted of a population-based
random sample of 20% of the female aged 50 years or older
since December 2, 2004 without an osteoporosis diagnosis
or an anti-osteoporotic prescription.
The index date was the first recorded visit for osteopo-
rosis or the first prescription of strontium ranelate or
alendronate sodium following this date, whichever came
first. For the non-osteoporotic cohort, the index date was a
computer-generated randomly dated in the first year after
study entry.
Osteoporosis was defined using a list of terms in the
Medical Directory for Regulatory Activities and then by
searching and validating the corresponding codes in Read/
OXMIS dictionaries used in the GPRD. For drug sub-
stances names from the World Health Organization Drug
Dictionary were used to identify and validate the
corresponding Multilex (UK) drug substance name, sub-
stance strength, and route of administration for product
terms used in the GPRD.
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The period defined as follow-up was from the index date to
the latest GPRD data collection or the patient’s transfer out
of the practice or death, whichever came first. The period of
treatment exposure (strontium ranelate or alendronate sodi-
um) was defined from the date of first prescription to the
date of last prescription plus the average prescription
duration. A 30-day time period was added to the end date,
as is usual when reporting adverse events. Moreover, current
exposure period (current users) was defined as the period
described above, and a non-exposure period (non-users) was
defined as the follow-up time outside this period, i.e., before
or after treatment exposure [20, 21]. The outcome of interest
was the first episode of VTE during exposure or follow-up
period. VTE events were defined using Read/OXMIS terms
and included deep venous thrombosis, pulmonary embolism,
or retinal vein thrombosis [22].
Confounders
The following known factors associated with the risk for VTE
were considered as potential confounding variables: age,
personalhistoryofVTE,pasthospitalisationsinthe12months
before the index date, previous referral to other specialities in
the 12 months before the index date, number of GP
consultations, fractures (lower limb, pelvis, or sacrum), major
surgery (including abdominal, pelvic, or spinal surgery),
malignant tumour, inflammatory bowel disease, varicose
veins,heart failure,cerebrovasculardiseases,atrialfibrillation,
smoking status, alcohol consumption, and BMI [2, 23–25].
Some prescriptions were also included as potential con-
founders:oestrogen replacement therapy for at least3 months,
number of previous osteoporotic treatments, and long-term
use (more than 3 months) of oral corticosteroids [23, 26]. All
covariates were assessed prior to the index date at any points
in the available history after the UTS date, except for
prescriptions, which were assessed in the 6 months prior to
the index date, and fractures and surgery, which were also
included whatever the time of occurrence.
Comparison groups
The incidence of VTE was compared between the untreated
osteoporotic cohort and the non-osteoporotic cohort. The
incidence of VTE in patients receiving strontium ranelate or
alendronate sodium was then compared with the incidence
in the untreated osteoporotic cohort.
Statistical analysis
The following analyses were conducted for each cohort:
descriptive statistics on characteristics at index date, annual
incidence of VTE expressed per 1,000 patient–years (PY) and
time to first VTE using Kaplan–Meier life-table analysis. A
Cox proportional hazards regression model was used to
compare risk for VTE between cohorts. As a first step, we
adjusted on age only since it is a well-known risk factor for
VTE [2, 23, 27, 28]. As a second step, risk factors and all
confounders described above were tested in univariate
analysis, and then included in backward selection to select
the final fully adjusted regression models. For the compar-
ison between the untreated osteoporotic and non-osteoporotic
cohorts, we excluded the factors potentially linked to the
osteoporosis itself (recent fractures and surgery during the
study and referrals to other specialities as rheumatology,
radiology, trauma, and orthopaedic clinic) in order to assess
the proper impact of the osteoporosis disease on the risk for
VTE and to avoid effects of over-matching. Sensitivity
analyses were provided within each drug cohort to compare
the incidence of VTE in current users versus non-users.
Results
The non-osteoporotic cohort comprised of 115,009 women.
There was a total of 58,242 osteoporotic patients, of whom
11,546 were untreated. The follow-up periods were
241,261 PY for the non-osteoporotic cohort and
10,979 PY for the untreated osteoporotic cohort. Consider-
ing only new users, a total of 2,408 osteoporotic patients
were treated with strontium ranelate and 20,084 with
alendronate sodium. The prescription period was
1,859 PY for strontium ranelate (mean follow-up,
9.3 months) and 19,391 PY for alendronate sodium (mean
follow-up, 11.6 months).
Table 1 summarises the baseline characteristics of the
four cohorts. Patients in the osteoporotic cohorts were older
than the non-osteoporotic cohort with a mean age of
74.1 years for osteoporotic patients treated with strontium
ranelate or alendronate sodium and 70.8 years for untreated
osteoporotic women versus 66.5 years for non-osteoporotic
women. The mean BMI was higher in the non-osteoporotic
cohort than in the untreated osteoporotic cohort. The
number of patients with a medical history of VTE was
higher in the untreated osteoporotic cohort (3.4%) than in
the non-osteoporotic cohort (1.6%). For treated osteoporot-
ic patients, the number of patients with a medical history of
VTE was 4.2% in the strontium ranelate cohort and 3.8% in
the alendronate sodium cohort. As would be expected, the
osteoporotic cohorts included a higher number of patients
with referrals to other services or specialities (such as
rheumatology, radiology, traumatology, orthopaedic clinic,
and X-ray), hospitalisations, fractures, and surgery. Simi-
larly, fewer non-osteoporotic women had received oral
corticosteroids within the 6 months before the index date.
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The annual incidence of VTE was 3.2 per 1,000 PY in
non-osteoporotic women versus 5.6 per 1,000 PY in
untreated osteoporotic patients. Table 2 shows the incidence
of VTE in non-osteoporotic patients and osteoporotic
untreated patients. Significant increased risk for VTE was
observed (relative risk: 1.75 [95% CI, 1.09–1.84]) in
untreated osteoporotic cohort versus the non-osteoporotic
cohort, which remained significant when adjusted for age
(hazard ratio (HR), 1.43 [95% CI, 1.10–1.86]). In fully
adjusted model, the difference was still significant (HR,
1.38 [95% CI, 1.03–1.86]). Figure 1 shows the cumulative
incidence curve of first VTE during the follow-up period
using Kaplan–Meier’s method.
The annual incidence of VTE increased with age in both
non-osteoporotic women and untreated osteoporotic
patients: 2.4 and 4.3 per 1,000 PY, respectively, in women
aged between 50 and 75 years; 5.2 and 7.2 per 1,000 PY in
women aged between 75 and 80; and 6.1 and 8.3 per
1,000 PY in women older than 80 years.
Comparison of the incidence of VTE in untreated
osteoporotic patients with the two cohorts of treated
patients showed no significant difference (Table 3), in both
the age-adjusted and in the fully adjusted models, and
whatever the treatment may be. In the strontium ranelate-
Table 1 Main characteristics of the cohorts at index date
Non-osteoporotic cohort Untreated osteoporotic cohort Treated osteoporotic cohort
Strontium ranelate Alendronate sodium
Number of patients 115,009 11,546 2,408 20,084
Age (years) 66.5±11.5 70.8±10.8 74.1±10.1 74.1±10.3
Patients ≥80 years 18,776 (16.3) 2,700 (23.4) 802 (33.3) 6,775 (33.7)
BMI, kg/m² 27.1±5.6 25.2±5.0 24.4±4.9 25.4±5.2
History of VTE 1,838 (1.6) 395 (3.4) 100 (4.2) 768 (3.8)
Medical history
Referrals
a, b 32,124 (27.9) 6,442 (55.8) 1,375 (57.1) 10,906 (54.3)
Hospitalisations
b 2,607 (2.3) 676 (5.9) 178 (7.4) 1,699 (8.5)
Fracture 3,100 (2.7) 1,181 (10.2) 323 (13.4) 2,785 (13.9)
Surgery 12,697 (11.0) 1,853 (16.0) 470 (19.5) 3,555 (17.7)
Malignant cancer 15,371 (13.4) 2,147 (18.6) 445 (18.5) 3,767 (18.8)
Varicose veins 8,247 (7.2) 1,238 (10.7) 302 (12.5) 2,215 (11.0)
Previous treatments
Oestrogen replacement therapy
c 8,874 (7.7) 582 (5.0) 74 (3.1) 546 (2.7)
Oral corticosteroids
c 2,966 (2.6) 825 (7.1) 406 (16.9) 4,474 (22.3)
Data are number (%) or mean ± standard deviation
VTE venous thromboembolism (including deep venous thrombosis, pulmonary embolism, or retinal vein thrombosis), BMI body mass index
aReferrals to other specialities (traumatology, radiology, and orthopaedic clinic)
bMedical events within 12 months prior to the index date
cPrescriptions ≥3 months, up to 6 months before the index date
Table 2 Incidence of VTE in non-osteoporotic women versus
untreated osteoporotic patients
Non-osteoporotic
cohort
(N=115,009)
Untreated osteoporotic
patients
(N=11,546)
Patients with VTE (N) 767 61
Annual incidence
(per 1,000 PY)
3.2 5.6
Relative risk (95% CI) 1.75 (1.09–1.84)
Adjusted model on age
a
HR (SE) 1.43 (0.13)
95% CI 1.10–1.86
p value 0.007
Fully adjusted model
b
HR (SE) 1.38 (0.15)
95% CI 1.03–1.86
p value 0.030
VTE venous thromboembolism (including deep venous thrombosis,
pulmonary embolism, or retinal vein thrombosis), CI confidence
interval, HR hazard ratio, SE standard error; PY patients–years
aHR between groups based on a Cox proportional hazards regression
model adjusted on age
bHR between groups based on a Cox proportional hazards regression
model fully adjusted for all confounders described in the Methods
section (final regression model by backward selection)
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with HRs of 1.15 (95% CI, 0.63–2.1) and 1.09 (95% CI,
0.60–2.01) in age-adjusted and fully adjusted models,
respectively, versus untreated osteoporotic women. In the
alendronate sodium-treated cohort, the incidence of VTE
was 7.2 per 1,000 PY and the HRs were 1.10 (95% CI,
0.81–1.50] and 0.92 (95% CI, 0.63–1.33) in age-adjusted
and fully adjusted models, respectively, versus untreated
osteoporotic women.
The rate of mortality was similar for both cohorts, which
are 2.9% in the strontium ranelate group and 4.0% in the
alendronate group.
Sensitivity analyses were performed within each cohort
of treated osteoporotic patients (Table 4). The incidence of
VTE during drug exposure (current users) was compared
with the incidence when not exposed either before the
beginning of the treatment or after treatment cessation (non-
users). No significant difference in the incidence of VTE
was observed between the current users and non-users of
strontium ranelate (6.8 versus 7.0 per 1,000 PY; HR, 0.90
[95% CI, 0.46–1.75]); similar results were obtained with
alendronate sodium (6.2 versus 7.2 per 1,000 PY; HR, 0.99
[95% CI, 0.80–1.23]).
Discussion
To our knowledge, this is the first study to compare the
incidence of VTE in osteoporotic and non-osteoporotic
women. We found a significant 43% increase in the age-
adjusted risk for VTE in untreated osteoporotic patients
versus non-osteoporotic women. The profiles of our cohorts
are consistent with the known major characteristics and risk
factors for VTE [2, 29, 30]. It is well-known that the risk
for VTE is increased in the elderly [23, 30], which is a
population exposed to an increasing number of risk factors
(e.g., fractures, hospitalisations, and heart disease). In our
study, the incidence of VTE in the non-osteoporotic cohort
was 2.4 per 1,000 PY for those aged 50 to 74 years, 5.2 per
1,000 PY between 75 and 80 years old, and 6.1 per
1,000 PY for those over 80 years. A similar increase was
observed in untreated osteoporotic patients from 4.3 to 8.3
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Table 3 Incidence of VTE in osteoporotic patients treated with
strontium ranelate or alendronate sodium versus untreated osteoporot-
ic patients
Treated osteoporotic patients Untreated
osteoporotic
patients
(N=11,546)
Strontium
ranelate
(N=2,408)
Alendronate
sodium
(N=20,084)
Patients with
VTE (N)
13 140 61
Annual incidence
(per 1,000 PY)
7.0 7.2 5.6
Adjusted model on age
a
HR (SE) 1.15 (0.31) 1.10 (0.16)
95% CI 0.63–2.10 0.81–1.50
p value 0.656 0.530
Fully adjusted
b
HR (SE) 1.09 (0.31) 0.92 (0.19)
95% CI 0.60–2.01) 0.63–1.33)
p value 0.773 0.646
VTE venous thromboembolism (including deep venous thrombosis,
pulmonary embolism, or retinal vein thrombosis, CI confidence
interval, HR hazard ratio, SE standard error, PY patients–years
aHR between groups based on a Cox proportional hazards regression
model adjusted on age
bHR between groups based on a Cox proportional hazards regression
model fully adjusted for all confounders described in the Methods
section (final regression model by backward selection)
Table 4 Incidence of VTE in current users versus non-users of
strontium ranelate or alendronate sodium
Treated osteoporotic patients
Strontium ranelate
(N=2,408)
Alendronate sodium
(N=20,084)
Non-
users
Current
users
Non-
users
Current
users
Patients with VTE (N) 34 13 230 140
Annual incidence
(per 1,000 PY)
6.8 7.0 6.2 7.2
HR (SE)
a 0.90 (0.34) 0.99 (0.11)
95% CI 0.46–1.75 0.80–1.23
p value 0.75 0.96
During treatment exposure, patients belong to the cohort of current
users; outside this period, they are considered as non-users
VTE venous thromboembolism (including deep venous thrombosis,
pulmonary embolism, or retinal vein thrombosis), CI confidence
interval, HR hazard ratio, SE standard error, PY patients–years
aHR between groups based on a Cox proportional hazards model
adjusted on age and with group included in a time-dependent fashion
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those over 80 years, respectively. These results are in the
same range to those described elsewhere [29, 31, 32].
History of previous VTE is a major risk factor of
recurrence of the condition [30]. In our study, the number
of patients with a previous medical history of VTE was
higher in the untreated osteoporotic patients than in the
non-osteoporotic patients. This could partly explain the
observations of further recurrence of VTE in untreated
osteoporotic patients. However, when the results were
adjusted for medical history of VTE and additional risk
factors, such as age, BMI, and use of oral corticosteroids
for more than 3 months, the risk of VTE was still higher in
untreated osteoporotic patients. These results suggest that if
these covariates participate in the risk of VTE, there is at
least another risk factor most likely related to osteoporotic
disease itself.
Osteoporotic patients, generally, have a poor gait, an
increased tendency to fall, and have related injuries such as
fractures [33]. For example, the lifetime risk of hip fracture
was estimated to be 17.5% in Caucasian women based on a
life expectancy of 78.9 years [34]. Thus, osteoporosis and
related health issues lead to decreased mobility, which is a
known risk factor for VTE. Moreover, trauma and ortho-
paedic surgery are among the strongest risk factors for VTE
[35, 36]. Indeed, several reports have described that surgery
is associated with a 6- to nearly 13-fold increased in the risk
of VTE [23, 26, 29]. Orthopaedic surgery of the hip and
knee has been reported to lead to thrombosis in 30% to 50%
of patients without thromboprophylaxis [2]. Therefore,
osteoporosis and its complications, fractures in particular,
appear to be associated with an increased risk for VTE.
Strontium ranelate is an anti-osteoporotic treatment for
which meta-analysis of the pivotal phase III clinical studies
indicated that the annual incidence of VTE was 0.9% over
5 years in the strontium ranelate group versus 0.6% in the
placebo group, with a relative risk of 1.4 (95% CI, 1.0–2.0)
[11]. There is no known rationale or clear explanation for
this difference in the incidence of VTE between strontium
ranelate and placebo. In a study performed in elderly
women, strontium ranelate did not affect global primary
and secondary haemostatic parameters [37]. In the present
study, there was no statistically significant difference in the
incidence of VTE between osteoporotic patients treated
with strontium ranelate and the untreated osteoporotic
cohort. These results are in accordance with a recent study
using a self-controlled case series method in the GPRD that
did not show a greater association of VTE with strontium
ranelate treatment [20]. In our study, we have included
larger population with a longer follow-up, and thus, results
are more informative and strengthened. Furthermore, the
incidence of VTE with strontium ranelate is very similar to
that for osteoporotic patients treated with alendronate
sodium, a treatment for which a greater association with
VTE has never been shown [38–40].
This study has some limitations since it is a retrospective
study cohort with no randomisation process to define the
populations and with incomplete or unmeasured confound-
ing factors such as severity of osteoporosis, immobilisation,
prolonged travel, and family history of VTE. To take into
account differences between treated and untreated groups,
multiple adjustments on risk factors of VTE have been
performed. However, even if the main risk factors have
been taken into account, we cannot rule out residual
confounding effect. In addition, as strontium ranelate is a
new anti-osteoporotic treatment the population treated with
strontium ranelate is smaller, and the mean follow-up
duration is shorter when compared to alendronate sodium
cohort studied. For these reasons, a certain imbalance in
analyses could not be excluded, and therefore, this study
does not provide the same level of proof than double-
blinded placebo controlled clinical trials.
However, we should note that the population profile of
this study is in conformity with what might be expected in
terms of characteristics and observed increased risk for
VTE with age. Furthermore, the fact that our study did not
show an association between strontium ranelate treatment
and increased risk for VTE, when compared with untreated
patients, is reinforced by robustness analyses demonstrating
no difference between current users and non-users. Finally,
the rates of mortality were similar in the two treated cohorts
(2.9% in the strontium ranelate cohort and 4.0% in the
alendronate sodium cohort) avoiding any doubts regarding
the potential under-reporting of VTE leading to death and
therefore, removing the bias of not diagnosed VTE.
In conclusion, this study shows for the first time that
osteoporosis is associated with increased risk for VTE,
probably related to the osteoporotic disease itself and its
associated comorbidities. In addition, our study suggests
that in current practice treatment with strontium ranelate
does not carry an additional risk of VTE compared to that
previously observed in clinical trials.
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